Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710973 | 0.80 | MEN1 (0.48) | MEN1KMT2AKDM4CP2RX3TGFBR1 | |
| SCHEMBL3177027 | 0.80 | PTGDR2 (0.43) | MEN1KMT2AKDM4CP2RX3TGFBR1 | |
| SCHEMBL7456689 | 0.78 | MEN1 (0.49) | MEN1KMT2AKDM4CP2RX3TGFBR1 | |
| SCHEMBL8195016 | 0.77 | MEN1 (0.46) | MEN1KMT2AKDM4CP2RX3 | |
| SCHEMBL8197550 | 0.75 | SIGMAR1 (0.49) | MEN1KMT2AKDM4CP2RX3TGFBR1 | |
| SCHEMBL29832042 | 0.75 | TGFBR1 (0.56) | MEN1KMT2AKDM4CTGFBR1NPC1 | |
| SCHEMBL31419834 | 0.74 | CYP1A2 (0.53) | MEN1KMT2ALMNARAB9ASMN1; SMN2 | |
| SCHEMBL4444887 | 0.74 | MEN1 (0.47) | MEN1KMT2AKDM4CP2RX3TGFBR1 | |
| SCHEMBL15244245 | 0.74 | MEN1 (0.40) | MEN1KMT2AKDM4CP2RX3NPC1 | |
| SCHEMBL10184237 | 0.74 | ALDH1A1 (0.57) | MEN1KMT2AKDM4CTGFBR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | MEN1 4009/4885KMT2A 3899/4885KDM4C 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.